Clinical Trial Update: Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Rituxan (rituximab) and Abraxane (nab-paclitaxel) for patients with inoperable stage III or metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Rituxan (rituximab)

Snippet

Sponsor: California Cancer Assocaties for Research & Excellence | Conditions: Malignant Melanoma of Skin Stage III, Metastatic Melanoma | Phase 2 | Status: UNKNOWN